Short communicationDNAJC13 mutation screening in patients with Parkinson's disease from South Italy
Introduction
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. This degeneration leads to bradykinesia, muscular rigidity, resting tremor, and postural instability. It affects 1–2% of the population above the age of 60. Although generally considered a sporadic disease, Mendelians forms of the disease are described. Rare highly-penetrant PD-causing mutations have been identified in several genes, in autosomal-recessive forms (PARK2, PINK1, and DJ1) or autosomal dominant forms (SNCA and LRRK2) [1]. The advent of innovative methods for sequencing analysis has led to a rapid increase in the number of genes involved in monogenic PD forms (VPS35, CHCHD2, TMEM230, SYNJ1, ATP13A2, FBXO7, DNAJC6). DNAJC13 has been identified as a novel gene implicated in late-onset Lewy body PD. The rare missense mutation p. N855S was identified through linkage analysis and exome sequencing of a large Saskatchewan Mennonite family, in which twelve out of 57 members had previously been diagnosed with PD. DnaJ (Hsp40) homolog, Subfamily C, Member 13 (DNAJC13) is an excellent PD candidate gene given its relationship with two pathways that are involved in disease pathogenesis: endosomal recycling system and the lysosomal system [2]. DNAJC13 is related to the retromer function via its interaction with the retromer component sorting nexin 1 [3] and it also binds (via its DNAJ domain) to the molecular chaperone heat shock cognate 70 (Hsc70) which is involved in the endosomal system [4]. To assess the clinical relevance and assess mutation frequency, DNAJC13 has been sequenced in a series of patients with clinical familial PD and sporadic PD from South Italy.
Section snippets
Patients and methods
To evaluate the presence of mutations in the DNAJC13 gene, we screened a PD group including 563 sporadic patients and 168 familial patients with clinically diagnosed PD (62% men; mean age, 66.4 ± 9.1 years; age at onset, mean 60.3 ± 10.2 years). All patients recruited at the Institute of Neurology, Department of Medical Sciences, University of Magna Graecia, Catanzaro met the UK Brain Bank criteria. Our population included 168 patients with familial PD, having at least 1 relative among their
Results
The p. N855S mutation was not identified in our patients but the sequencing analysis of 168 familial PD and 563 sporadic PD showed two carriers (in a familial case and in a sporadic case) of p. R903K variant in exon 24 of the DNAJC13 gene, highlighting the conserved nature of this region of the gene/protein (Fig. 1b and c). The pathogenic potential of the identified variant was predicted using Mutation Taster Server (http://www.mutationtaster.org), Polyphen (http://genetics.bwh.harvard.edu/pph2/
Discussion
DNAJC13 has recently been proposed as a novel gene implicated in an autosomal dominant form of PD. A subsequent multi-ethnic case-control study performed by the same group on subjects from Canada, Norway, Taiwan, Tunisia and USA identified the p. N855S variant and other two missense mutations (p.W1082I, p. R2115L) with uncertain roles [2].
DNAJC13 parkinsonism and idiopathic PD appear to be clinically and pathologically similar at pathological examination, indicating a brainstem or transitional
Disclosure
The authors declare no financial or other conflict of interests
References (11)
Genetics of Parkinson's disease–state of the art, 2013
Parkinsonism Relat Disord.
(2014 Jan)- et al.
The DnaJ-domain protein RME-8 functions in endosomal trafficking
J. Biol. Chem.
(2005) - et al.
DnaJ/Hsp40 family and Parkinson's disease
Front. Neurosci.
(2018) - et al.
DNAJC13 mutations in Parkinson disease
Hum. Mol. Genet.
(2014 Apr 1) - et al.
Analysis of articulation between clathrin and retromer in retrograde sorting on early endosomes
Traffic
(2009)
Cited by (9)
Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics
2023, Ageing Research ReviewsAssociation study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease
2021, Neurobiology of AgingCitation Excerpt :Their discovery shares several similarities, including the presumed role of loss of function, missense mutations, and dominant heritability (Nalls et al., 2019). Subsequent studies, in many cases, failed to replicate the association of these genes with PD (Bartonikova et al., 2018; Gagliardi et al., 2018; Kruger et al., 2011; Nichols et al., 2015; Nuytemans et al., 2013; Sun et al., 2014). However, ongoing studies, including those using cellular and animal models, continue to refer to these genes as PD-associated genes and to invoke their function in PD-related mechanisms (Chen et al., 2018; Tran et al., 2018).
Post-translational modifications of Hsp70 family proteins: Expanding the chaperone code
2020, Journal of Biological ChemistryAnalysis of the TMEM230 gene in familial Parkinson's disease from south Italy
2019, Journal of the Neurological SciencesThe genetic landscape of Parkinson's disease
2018, Revue NeurologiqueCitation Excerpt :The mean age at onset was 65 years (range: 40 to 85 years). Patients presented asymmetric signs at onset with bradykinesia, tremor, rigidity with a good response to levodopa and postural instability [67–69]. Three patients had dementia, but this occurred much later in the disease course [68].
- 1
These authors contributed equally to this work.